A Pancreatic Cancer Revolution

 https://www.wsj.com/opinion/fda-approves-daraxonrasib-pancreatic-cancer-drug-revolution-medicines-5a7ff903?mod=hp_opin_pos_5

Pancreatic cancer has long been an agonizing death sentence, but it could be commuted by novel treatments and earlier detection. That’s the hope after the Food and Drug Administration on Wednesday approved Revolution Medicines’s novel drug, daraxonrasib, which doubled survival time in a late-stage trial for patients with advanced pancreatic cancer.

Oncologists herald the small-molecule pill as a revolution in pancreatic cancer care. The prognosis for pancreatic cancer is typically bleak, with a five-year survival rate of about 3% for Stage 4. Patients fare better if their cancers are caught early (40%), but very few are.